Imlunestrant + Abemaciclib for Breast Cancer
(EMBER-3 Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should have progressed on certain treatments, which might imply changes in medication. It's best to discuss your specific situation with the trial team.
What data supports the effectiveness of the drug combination Imlunestrant and Abemaciclib for breast cancer?
Research shows that Abemaciclib, when used with other treatments like fulvestrant or letrozole, significantly improves progression-free survival in women with hormone receptor-positive, HER2-negative advanced breast cancer. This suggests that Abemaciclib is effective in treating similar types of breast cancer.12345
Is the combination of Imlunestrant and Abemaciclib safe for humans?
Abemaciclib, when used with other treatments for breast cancer, has shown a generally tolerable safety profile, with common side effects including diarrhea and low white blood cell counts. Most side effects were mild, but some, like neutropenia (low levels of a type of white blood cell), were more severe in a smaller number of patients.15678
What makes the drug combination of Imlunestrant and Abemaciclib unique for breast cancer treatment?
The combination of Imlunestrant and Abemaciclib is unique because it pairs a novel estrogen receptor degrader (Imlunestrant) with a cyclin-dependent kinase 4 and 6 inhibitor (Abemaciclib), which together target hormone receptor-positive, HER2-negative breast cancer by both blocking estrogen's effects and inhibiting cancer cell growth.14579
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for postmenopausal women with advanced breast cancer that's ER+ and HER2-. They should have seen their cancer progress after aromatase inhibitor treatment, possibly combined with a CDK4/6 inhibitor. Participants must be able to take pills, have measurable disease or bone-only disease, and be in good physical condition (ECOG 0-1). They can't join if they've had certain prior treatments like chemotherapy or specific inhibitors, have severe brain metastasis, visceral crisis, lung complications from cancer spread, or serious medical conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive imlunestrant, investigator's choice of endocrine therapy, or imlunestrant plus abemaciclib
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- Abemaciclib
- Exemestane
- Fulvestrant
- Imlunestrant
Exemestane is already approved in European Union, United States, Canada, Japan for the following indications:
- Early breast cancer
- Advanced breast cancer
- Early breast cancer
- Advanced breast cancer
- Early breast cancer
- Advanced breast cancer
- Early breast cancer
- Advanced breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University